Conference Nordic HPB - NOLCA, BERGEN

19 – 20 September 2024

Thursday 19 September

08.30                  Registration

09.00                  Welcome by Jon-Helge Angelsen and Roland Andersson

PANCREATIC CANCER Chair: Jon-Helge Angelsen

09.10 - 09.30 Radiomics and Deep learning in Pancreatic cancer – Will AI replace the radiologist? Marjolein Henrieke Liedenbaum, Bergen

09.30 - 09.50 NORPACT-II and the way beyond for non metastatic PDAC Knut Jørgen Labori, Oslo

09.50 - 10.10 Clinical relevance of circulating tumor DNA in pancreatic cancer. Oddmund Nordgård, Stavanger

10.10 - 10.30 When to start or stop surveillance of 5 mm small IPMN? Claus Fristrup, Odense

10.30 – 11.00      Coffee/exhibition

 ENDOSCOPY AND PANCREATIC COMPLICATIONS Chair: Ernesto Sparrelid

11.00 – 11.20 Endoscopic ultrasound and FNB in cystic lesions (zoom link) Roald Havre, Bergen

11.20 - 11.40 EUS-guided Radiofrequency ablation of pancreatic NETs (zoom link) Khanh Do-Cong Pham, Bergen

11.40 - 12.00 Pancreatic fistula prediction, prevention, classification – Quo vadis?” Ville Sallinen, Helsinki

12.00 - 12.15 Complications in pancreatic surgery: Case presentations, Dyre Kleive and Jon-Helge Angelsen, Bergen

12.15 - 12.30 Presidential adress. Roland Andersson, Lund

12.30 – 13.30      Lunch/exhibition

ROBOTIC /MINI INVASIVE HPB SURGERY Chair: Bjørn Edwin

13.30 - 13.50 Establishing Robotic HPB surgery: Experience from Bergen. Jon-Helge Angelsen and Kim Waardal, Bergen

13.50 - 14.10 Robotic HPB surgery - the Stockholm experience after 500 resections Stephan Gilg, Stockholm

14.10 - 14.30 Robotic pancreatoduodenectomy: Fully robotic vs robot assisted? Bergtor Björnsson, Linköping

14.30 - 14.45 A critical appraisal of robotic vs. laparoscopic HPB surgery. Åsmund Fretland, Oslo

14.45 - 15.00 Plenary discussion "Is robotic surgery to the best for the patient, for the surgeon, or for both?" TBA

15.00 – 15.30      Coffee/exhibition

YOUNG INVESTIGATORS: FREE PAPERS I Chair: Oddvar Sandvik

15.30 - 15.40 I: Impact of pancreas transection site on incidence of PF after distal pancreatectomy: a propensity score matched study. Trond Kjeseth, Stavanger 

15.40 - 15.50 II: Liver ablation, results from University of Northern Norway, Tromsø Brage Bårdsen, Tromso

15.50 - 16.00 III: International external validation and model update for the distal pancreatectomy fistula risk scores (DISPAIR and D-FRS) Akseli Bonsdorff, Helsinki

16.00 - 16.10 IV: Preoperative fistula risk score for pancreatoduodenectomy – Nordic multicenter study. Tiia Ojala, Helsinki

16.10 - 16.20 V: V: Experimental treatment for non-resectable CRLM: the Excalibur trial. Anne Longva, Oslo

16.20 - 16.30 VI: Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the outcome of pancreatic cancer patients: a retrospective populational study. Anni Varhe, Helsinki

16.30 – 16.40 Short break

16.40 – 17.00      Most important papers in HPB 2023-2024, Ville Sallinen, Helsinki

17.00 – 17.20      General Assembly of Nordic Chapter of IHPBA, Roland Andersson, Lund

17.20 - 18.00 Nordic Pancreatic Cancer Network , Roland Andersson, Lund

19.30 - 22.00       Dinner at Hotel Norge

Friday 20 September

NOLCA Chair: Per Stål and Malin Sternby Eilard

 08.30 - 08.35 Welcome, Per Stål, Stockholm

08.35 - 09.00 Diagnosis and staging of HCC in cirrhotic and noncirrhotic liver with an emphasis on LIRADS, Nikolaos Kartalis, Stockholm

09.00 - 09.20 Adjuvant (or neoadjuvant) treatment following resection or ablation of HCC, Pia Österlund, Helsinki

09.20 - 09.35 Risk factors for recurrence after curative intent treatments of HCC, Peter Jepsen, Aarhus

09.35 - 09.50 HCC screening in Sweden – a case-control study on the impact of ultrasound screening on HCC-related mortality, Hannes Hegmar, Stockholm

09.50 - 10.15 Coffee break

 

Chair: Åsmund Avdem Fretland and Ida Björk

10.15 - 10.30 TESLA-trial: Liver transplantation for CCA, Sheraz Yaqub, Oslo

10.30 - 10.45 TOMCAT-trial: SIRT og HAI for CCA, Kristoffer Lassen, Oslo

10.45 - 11.00 Klatskin tumor: pre- and postoperative prognostic factors, Hasan Ahmad Al-Saffar, Copenhagen

11.00 - 11.30 State of the art lecture: Perioperative therapy for cholangiocarcinoma, Flavio Rocha, Oregon, USA

11.30 - 11.45 General Assembly NOLCA, Per Stål, Stockholm

11.45 - 12.45 Lunch and exhibition

Chair: Sheraz Yaqub

12.45 - 13.00 Risk of HCC and CCA in Danish and English patients with ALD cirrhosis, Morten D Jensen, Aarhus

13.00 - 13.15 Gall bladder cancer in Finland, Sini Takala, Helsinki

COLORECTAL LIVER METASTASES

13.15 - 13.35 Simultaneos resection for CLM - Results from a Norwegian national cohort of 200 patients, Jon-Helge Angelsen, Bergen

13.35 - 13.55 Metachronous recurrence pattern in 5500 patients from Central Norway, radically treated for colorectal cancer 2001-2015, Per Eivind Storli, Trondheim

13.55 - 14.00 Summing up, Roland Andersson and Jon-Helge Angelsen